{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-075162","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.154103+00:00","generated_at":"2026-06-01T01:23:34.876040+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Protagonist Therapeutics shareholders approve doubling of authorized common shares to 180M","bullets":["Shareholders approved amendment to increase authorized common shares from 90M to 180M, effective June 21, 2024.","Three Class II directors elected: Sarah O'Dowd, William Waddill, and Rusty Williams.","Advisory vote on executive compensation approved: 33.9M for, 9.3M against.","Ratification of Ernst & Young as independent auditor for FY2024 approved: 49.3M for, 115k against.","All four proposals passed; no other matters submitted at annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-075162","json":"https://secwatch.observer/filing/0001104659-24-075162.json","markdown":"https://secwatch.observer/filing/0001104659-24-075162.md","text":"https://secwatch.observer/filing/0001104659-24-075162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/0001104659-24-075162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924075162/tm2418234d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T01:23:34.876040+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}